110 related articles for article (PubMed ID: 20483154)
1. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
Gupta S; Wang Y; Ramos-Garcia R; Shevrin D; Nelson JB; Wang Z
Prostate; 2010 Oct; 70(14):1575-85. PubMed ID: 20564326
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia.
Zong HT; Peng XX; Yang CC; Zhang Y
Asian J Androl; 2011 Nov; 13(6):812-8. PubMed ID: 21892196
[TBL] [Abstract][Full Text] [Related]
3. [Natural 5α-reductase inhibitors in treatment of benign prostatic hyperplasia].
Zheng RR; Ouyang QX; Liu ZY; Li LN; Yang L; Wang ZT
Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):858-867. PubMed ID: 38621893
[TBL] [Abstract][Full Text] [Related]
4. [Effect of auricular acupressure combined with 5α-reductase inhibitor on short-term quality of life of patients after transurethral plasmakinetic enucleation of the prostate].
Xue YF; Fan YX; Wang R
Zhonghua Nan Ke Xue; 2023 Jul; 29(7):609-614. PubMed ID: 38619407
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases.
Yang DY; Seo WW; Park RW; Rhee SY; Cha JM; Hah YS; Jeong CW; Kim KJ; Yang HJ; Kim DK; Ha JY
World J Mens Health; 2024 May; ():. PubMed ID: 38772542
[TBL] [Abstract][Full Text] [Related]
6. Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging.
Loeb S; Kettermann A; Carter HB; Ferrucci L; Metter EJ; Walsh PC
J Urol; 2008 Oct; 180(4):1314-7; discussion 1317. PubMed ID: 18707733
[TBL] [Abstract][Full Text] [Related]
7. Determination of the potency of a novel saw palmetto supercritical CO2 extract (SPSE) for 5α-reductase isoform II inhibition using a cell-free in vitro test system.
Pais P; Villar A; Rull S
Res Rep Urol; 2016; 8():41-9. PubMed ID: 27186566
[TBL] [Abstract][Full Text] [Related]
8. Association of 5α-Reductase Inhibitors with Depression and Suicide: A Mini Systematic Review and Meta-analysis.
Uleri A; Cornu JN; Gobbo A; Herrmann TRW; De Nunzio C; Hashim H; Baboudjian M
Eur Urol Focus; 2024 Apr; ():. PubMed ID: 38692949
[TBL] [Abstract][Full Text] [Related]
9. The post-finasteride syndrome: possible etiological mechanisms and symptoms.
Leliefeld HHJ; Debruyne FMJ; Reisman Y
Int J Impot Res; 2023 Sep; ():. PubMed ID: 37697052
[TBL] [Abstract][Full Text] [Related]
10. Eight Misconceptions about Prostate-Specific Antigen.
Vickers AJ; Lilja H
Clin Chem; 2024 Jan; 70(1):13-16. PubMed ID: 38175588
[No Abstract] [Full Text] [Related]
11. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
12. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer.
Kaplan SA; Lee RK; Chung DE; Te AE; Scherr DS; Tewari A; Vaughan ED
J Urol; 2012 Sep; 188(3):757-61. PubMed ID: 22818135
[TBL] [Abstract][Full Text] [Related]
13. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
14. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Helfand BT; Blackwell RH; McVary KT
J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
[TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
Andriole GL; Marberger M; Roehrborn CG
J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
[TBL] [Abstract][Full Text] [Related]
16. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
Marks LS; Andriole GL; Fitzpatrick JM; Schulman CC; Roehrborn CG
J Urol; 2006 Sep; 176(3):868-74. PubMed ID: 16890642
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
